The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Polyamines and cancer: old molecules, new understanding
Gerner, E. W., & Meyskens, F. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1454 · Cited by 1,159
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,047
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
Marie, J. C., Letterio, J. J., Gavin, M., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 985
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Iellem, A., Mariani, M., Lang, R., Recalde, H., Panina-Bordignon, P., Sinigaglia, F., & D'Ambrosio, D. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.847 · Cited by 914
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
(2000) · PubMed · Cited by 706
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 699
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H., & Russell, S. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53940-5 · Cited by 619
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609
Piccirillo, C. A., Letterio, J. J., Thornton, A. M., McHugh, R. S., Mamura, M., Mizuhara, H., & Shevach, E. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020590 · Cited by 594
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Baratelli, F., Lin, Y., Zhu, L., Yang, S.-C., Heuzé-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., & Dubinett, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1483 · Cited by 573
Blaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 561
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation
Gorelik, L., Constant, S., & Flavell, R. A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012076 · Cited by 521
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., Mazzoni, A., Segal, D. M., Staib, C., Lowel, M., Sutter, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.270 · Cited by 513
Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine
Rodriguez, P. C., Zea, A. H., Culotta, K. S., Zabaleta, J., Ochoa, J. B., & Ochoa, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110675200 · Cited by 509
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Sharma, S., Yang, S.-C., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., Huang, M., Batra, R. K., & Dubinett, S. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0141 · Cited by 506
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Sinha, P., Clements, V. K., & Ostrand-Rosenberg, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.636 · Cited by 466
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
De Clercq, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1134 · Cited by 460
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Laouar, Y., Sutterwala, F. S., Gorelik, L., & Flavell, R. A. (2005) · Nature Immunology · doi:10.1038/ni1197 · Cited by 451
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Sugimoto, H., Oda, S.-I., Otsuki, T., Hino, T., Yoshida, T., & Shiro, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508996103 · Cited by 441
DaCosta Byfield, S., Major, C., Laping, N. J., & Roberts, A. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.744 · Cited by 414
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., & Rowley, D. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1486 · Cited by 403
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer-Galetti, T., Pagano, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 396
Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor
Kennedy, C. R. J., Zhang, Y., Brandon, S., Guan, Y., Coffee, K., Funk, C. D., Magnuson, M. A., Oates, J. A., Breyer, M. D., & Breyer, R. M. (1999) · Nature Medicine · doi:10.1038/5583 · Cited by 391
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
Braun, D., Longman, R. S., & Albert, M. L. (2005) · Blood · doi:10.1182/blood-2005-03-0979 · Cited by 391
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Cutting Edge: TGF-β Inhibits Th Type 2 Development Through Inhibition of GATA-3 Expression
Gorelik, L., Fields, P. E., & Flavell, R. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.4773 · Cited by 390
Lee, I., Wang, L., Wells, A. D., Dorf, M. E., Ozkaynak, E., & Hancock, W. W. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041709 · Cited by 371
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315
Chang, C., Liao, J. C., & Kuo, L. (2001) · PubMed · Cited by 294
Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
Mellor, A. L. (2004) · International Immunology · doi:10.1093/intimm/dxh140 · Cited by 288
Cady, S. G., & Sono, M. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90142-6 · Cited by 285
De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M. P., Iezzi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409783102 · Cited by 284
Seddon, B., & Mason, D. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.279 · Cited by 255
Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R. L., Morrow, J. D., Shyr, Y., Boothby, M., Joyce, S., Carbone, D. P., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16492 · Cited by 250
Dikov, M. M., Ohm, J. E., Ray, N., Tchekneva, E. E., Burlison, J., Moghanaki, D., Nadaf, S., & Carbone, D. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.215 · Cited by 244
Targeting the TGFβ signaling network in human neoplasia
Dumont, N., & Arteaga, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00135-1 · Cited by 242
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Ozaki, Y., Edelstein, M. P., & Duch, D. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1242 · Cited by 240
Arginases I and II: do their functions overlap?
Cederbaum, S. D., Yu, H., Grody, W. W., Kern, R. M., Yoo, P., & Iyer, R. K. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.10.012 · Cited by 236
Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin.
O'Brien, T. G., Megosh, L. C., Gilliard, G., & Soler, A. P. (1997) · PubMed · Cited by 233
Type I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase
Yi, J. Y., Shin, I., & Arteaga, C. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413223200 · Cited by 228
Fiorucci, S., Santucci, L., Gresele, P., Faccino, R. M., del Soldato, P., & Morelli, A. (2003) · Gastroenterology · doi:10.1053/gast.2003.50096 · Cited by 224
Sonoki, T., Nagasaki, A., Gotoh, T., Takiguchi, M., Takeya, M., Matsuzaki, H., & Mori, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3689 · Cited by 217
Cyclooxygenase-2 as a target for anticancer drug development
Méric, J.-B., Rottey, S., Olaussen, K., Soria, J.-C., Khayat, D., Rixe, O., & Spano, J.-P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.003 · Cited by 217
TGF-β1 regulation of dendritic cells
Strobl, H., & Knapp, W. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00256-7 · Cited by 216
Fallarino, F., Asselin-Paturel, C., Vacca, C., Bianchi, R., Gizzi, S., Fioretti, M. C., Trinchieri, G., Grohmann, U., & Puccetti, P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3748 · Cited by 211
Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling
Nefedova, Y., Cheng, P., Gilkes, D., Blaskovich, M., Beg, A. A., Sebti, S. M., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4338 · Cited by 196
Macrophage arginine metabolism and the inhibition or stimulation of cancer
Mills, C. D., Shearer, J., Evans, R., & Caldwell, M. D. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.8.2709 · Cited by 191
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Di Costanzo, L., Sabio, G., Mora, A., Rodriguez, P. C., Ochoa, A. C., Centeno, F., & Christianson, D. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504027102 · Cited by 187
Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344
Brodmerkel, C. M., Huber, R., Covington, M., Diamond, S., Hall, L., Collins, R., Leffet, L., Gallagher, K., Feldman, P., Collier, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5370 · Cited by 186
Self-citationSingh, R., Pervin, S., Karimi, A., Cederbaum, S. D., & Chaudhuri, G. (2000) · PubMed · Cited by 185
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Emens, L. A., & Jaffee, E. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1797 · Cited by 182
Structure−Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors
Gaspari, P., Banerjee, T., Malachowski, W. P., Muller, A. J., Prendergast, G. C., DuHadaway, J., Bennett, S., & Donovan, A. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0508888 · Cited by 182
Self-citationBaban, B., Hansen, A. M., Chandler, P. R., Manlapat, A., Bingaman, A., Kahler, D. J., Munn, D. H., & Mellor, A. L. (2005) · International Immunology · doi:10.1093/intimm/dxh271 · Cited by 178
Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO
Wingender, G., Garbi, N., Schumak, B., Jüngerkes, F., Endl, E., von Bubnoff, D., Steitz, J., Striegler, J., Moldenhauer, G., Tüting, T., et al. (2006) · European Journal of Immunology · doi:10.1002/eji.200535602 · Cited by 170
Pockaj, B. A., Basu, G. D., Pathangey, L. B., Gray, R. J., Hernandez, J. L., Gendler, S. J., & Mukherjee, P. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.05.027 · Cited by 168
Astigiano, S., Morandi, B., Costa, R., Mastracci, L., D'Agostino, A., Ratto, G. B., Melioli, G., & Frumento, G. (2005) · Neoplasia · doi:10.1593/neo.04658 · Cited by 163
Indoleamine 2,3 dioxygenase and regulation of T cell immunity
Mellor, A. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.232 · Cited by 149
MOKYR, M. B., Kalinichenko, T. V., Gorelik, L., & Bluestone, J. A. (1998) · PubMed · Cited by 147
Ostrand‐Rosenberg, S., Grusby, M. J., & Clements, V. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6015 · Cited by 143
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
Muller, A. J., Malachowski, W. P., & Prendergast, G. C. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.831 · Cited by 124
Self-citationCsiki, I., Morrow, J. D., Sandler, A. B., Shyr, Y., Oates, J., Williams, M. K., Dang, T. P., Carbone, D. P., & Johnson, D. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0436 · Cited by 120
Tumor-Derived TGF-β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine
Kao, J. Y., Gong, Y., Chen, C.-M., Zheng, Q.-D., & Chen, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3806 · Cited by 119
Marrying Immunotherapy with Chemotherapy: Why Say IDO?
Muller, A. J., & Prendergast, G. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2213 · Cited by 117
Self-citationNon‐steroidal anti‐inflammatory drugs for the prevention and treatment of cancer
Pereg, D., & Lishner, M. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01519.x · Cited by 115
Ostrand‐Rosenberg, S., Clements, V. K., Terabe, M., Park, J. M., Berzofsky, J. A., & Dissanayake, S. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5796 · Cited by 112
Classical and Slow-Binding Inhibitors of Human Type II Arginase
Colleluori, D. M., & Ash, D. E. (2001) · Biochemistry · doi:10.1021/bi010783g · Cited by 111
THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivo
Burke, F., Knowles, R. G., East, N., & Balkwill, F. R. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600117 · Cited by 94
The immunoregulatory role of IDO-producing human dendritic cells revisited
Terness, P., Chuang, J.-J., & Opelz, G. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.12.006 · Cited by 89
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong, P. A., Tanaka, T. N., Kruklitis, R. J., Henry, A. C., Kapoor, V., Kaiser, L. R., Sterman, D. H., & Albelda, S. Μ. (2003) · PubMed · Cited by 89
Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Itokawa, T., Nokihara, H., Nishioka, Y., Sone, S., Iwamoto, Y., Yamada, Y., Cherrington, J. M., McMahon, G., Shibuya, M., Kuwano, M., et al. (2002) · PubMed · Cited by 84
TGF-β inhibitors for the treatment of cancer
Lahn, M. M. F., Kloeker, S., & Berry, B. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.629 · Cited by 84
Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice
Kacha, A. K., Fallarino, F., Markiewicz, M. A., & Gajewski, T. F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6024 · Cited by 83
Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine
Haas, A. R., Sun, J., Vachani, A., Wallace, A. F., Silverberg, M. B., Kapoor, V., & Albelda, S. Μ. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1178 · Cited by 82
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
Ferrari, V. D., Valcamonico, F., Amoroso, V., Simoncini, E., Vassalli, L., Marpicati, P., Rangoni, G., Grisanti, S., Tiberio, G. A., Nodari, F., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0028-1 · Cited by 79
Rodríguez, P. C., & Ochoa, A. C. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.10.001 · Cited by 76
Fallarino, F., Orabona, C., Vacca, C., Bianchi, R., Gizzi, S., Asselin‐Paturel, C., Fioretti, M. C., Trinchieri, G., Grohmann, U., & Puccetti, P. (2005) · International Immunology · doi:10.1093/intimm/dxh321 · Cited by 76
Kuroda, E., Sugiura, T., Okada, K., Zeki, K., & Yamashita, U. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1650 · Cited by 72
Safeguarding Patients in Clinical Trials with High Mortality Rates
Freeman, B. D., Danner, R. L., BANKS, S. M., & Natanson, C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.2.2011028 · Cited by 68
Cyclooxygenase inhibitors modulate NK activities that control metastatic disease
Kundu, N., Walser, T. C., Ma, X., & Fulton, A. M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0669-2 · Cited by 68
Cyclooxygenase 2 Inhibition Promotes IFN-γ-Dependent Enhancement of Antitumor Responses
Sharma, S. P., Zhu, L. X., Yang, S.-C., Zhang, L., Lin, J. F.-H., Hillinger, S., Gardner, B. K., Reckamp, K. L., Strieter, R. M., Huang, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.813 · Cited by 68
Zeytin, H. E., Patel, A. C., Rogers, C. J., Canter, D. J., Hursting, S. D., Schlom, J., & Greiner, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3878 · Cited by 67
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway
O’Shea, J. J., Park, H., Pesu, M., Borie, D. C., & Changelian, P. S. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000160781.07174.db · Cited by 63
Inhibitors of human indoleamine 2,3‐dioxygenase identified with a target‐based screen in yeast
Vottero, E., Balgi, A. D., Woods, K., Tugendreich, S., Mélèse, T., Andersen, R. J., Mauk, A. G., & Roberge, M. (2006) · Biotechnology Journal · doi:10.1002/biot.200600001 · Cited by 57
Nugent, F. W., Mertens, W. C., Graziano, S. L., Levitan, N. I., Collea, R., Gajra, A., Marshall, J., & McCann, J. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.004 · Cited by 50
Moali, C., Brollo, M., Custot, J., Sari, M., Boucher, J., Stuehr, D. J., & Mansuy, D. (2000) · Biochemistry · doi:10.1021/bi992992v · Cited by 49
Gasparini, G., Meo, S., Cornelia, G., Stani, S. C., Mariani, L., Gamucci, T., Avallone, A., Vullo, S. L., Mansueto, G., Bonginelli, P., et al. (2005) · The Cancer Journal · doi:10.1097/00130404-200505000-00007 · Cited by 34
Induction of antitumor immunity by indomethacin
Yacovlev, E., Gelfand, Y., Morecki, S., et al. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050009 · Cited by 34
Gasparini, G., Gattuso, D., Morabito, A., Longo, R., Torino, F., Sarmiento, R., Vitale, S., Gamucci, T., & Mariani, L. (2005) · The Oncologist · doi:10.1634/theoncologist.10-9-710 · Cited by 22
Malachowski, W. P., Metz, R., Prendergast, G. C., & Muller, A. J. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.09.918200 · Cited by 15
Self-citation
Cited by
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., Li, T., & Yin, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00013 · Cited by 1,298
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Metadata
- Authors
- Muller, A. J., & Scherle, P. A.
- Venue
- Nature Reviews Cancer
- Published
- 2006-08-01
- Volume
- 6
- Issue
- 8
- Pages
- 613-625
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1976707323
- Cited by
- 262
- References
- 139
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.